76.10
0.22%
+0.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$75.93
Aprire:
$76.28
Volume 24 ore:
941.36K
Capitalizzazione di mercato:
$17.76B
Reddito:
$3.97B
Utile/perdita netta:
$515.10M
Rapporto P/E:
39.43
EPS:
1.93
Flusso di cassa netto:
$858.70M
1 W Prestazione:
+0.44%
1M Prestazione:
-2.41%
6M Prestazione:
+11.31%
1 anno Prestazione:
-9.12%
Hologic, Inc. Stock (HOLX) Company Profile
Nome
Hologic, Inc.
Settore
Industria
Telefono
508-263-2900
Indirizzo
250 Campus Drive, Marlborough, MA
Hologic, Inc. Stock (HOLX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-07-14 | Aggiornamento | Needham | Hold → Buy |
2022-12-07 | Iniziato | RBC Capital Mkts | Sector Perform |
2022-10-13 | Iniziato | Mizuho | Buy |
2022-07-20 | Downgrade | BofA Securities | Buy → Neutral |
2022-07-20 | Iniziato | UBS | Neutral |
2022-07-18 | Downgrade | BTIG Research | Buy → Neutral |
2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2022-04-04 | Downgrade | Evercore ISI | Outperform → In-line |
2021-12-15 | Downgrade | Citigroup | Buy → Neutral |
2021-10-15 | Ripresa | Cowen | Outperform |
2021-10-14 | Iniziato | Redburn | Neutral |
2021-07-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
2020-11-20 | Downgrade | Needham | Buy → Hold |
2020-11-05 | Reiterato | Needham | Buy |
2020-06-30 | Aggiornamento | Cowen | Market Perform → Outperform |
2020-06-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2020-04-30 | Reiterato | Needham | Buy |
2020-04-30 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2020-04-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2020-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2020-01-13 | Reiterato | Needham | Buy |
2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
2020-01-07 | Iniziato | Citigroup | Buy |
2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
2019-09-26 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2019-08-01 | Reiterato | Needham | Buy |
2019-05-02 | Reiterato | Needham | Buy |
2019-01-31 | Reiterato | Needham | Buy |
2019-01-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2018-10-09 | Iniziato | UBS | Neutral |
2018-09-13 | Downgrade | BofA/Merrill | Buy → Neutral |
Mostra tutto
Hologic, Inc. Borsa (HOLX) Ultime notizie
A Dive into Hologic (HOLX) International Revenue Trends and Forecasts
Zacks Investment Research
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Zacks Investment Research
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
Zacks Investment Research
Deep Dive Into Hologic Stock: Analyst Perspectives (4 Ratings)
Benzinga
Hologic (HOLX) Reports Q2 Earnings: What Key Metrics Have to Say
Zacks Investment Research
Hologic (HOLX) Q2 Earnings and Revenues Beat Estimates
Zacks Investment Research
Hologic, Inc. Azioni (HOLX) Dati Finanziari
Hologic, Inc. (HOLX) Reddito 2024
HOLX ha riportato un ricavo (TTM) di $3.97 miliardi per il trimestre terminato il 2023-12-31, un -11.12% declino anno su anno.
Hologic, Inc. (HOLX) Reddito netto 2024
HOLX l'utile netto (TTM) è stato di $515.10 milioni per il trimestre terminato il 2023-12-31, un -47.98% diminuire anno su anno.
Hologic, Inc. (HOLX) Flusso di cassa 2024
HOLX ha registrato un flusso di cassa disponibile (TTM) di $858.70 milioni per il trimestre conclusosi con 2023-12-31, un -49.37% diminuire anno su anno.
Hologic, Inc. (HOLX) Utile per azione 2024
L'utile per azione (TTM) di HOLX è stato pari a $2.11 per il trimestre terminato il 2023-12-31, un -46.17% declino anno su anno.
Hologic, Inc. Azioni (HOLX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
GARRETT SCOTT T | Director |
Mar 14 '24 |
Option Exercise |
30.93 |
16,441 |
508,471 |
65,052 |
GARRETT SCOTT T | Director |
Mar 14 '24 |
Sale |
75.50 |
16,441 |
1,241,296 |
48,611 |
CRAWFORD SALLY | Director |
Mar 08 '24 |
Option Exercise |
26.74 |
9,039 |
241,703 |
141,966 |
CRAWFORD SALLY | Director |
Mar 08 '24 |
Sale |
76.40 |
9,039 |
690,607 |
132,927 |
Dockendorff Charles J | Director |
Mar 08 '24 |
Sale |
76.21 |
1,465 |
111,648 |
1,572 |
Oberton Karleen Marie | Chief Financial Officer |
Jan 29 '24 |
Sale |
75.00 |
14,940 |
1,120,500 |
103,916 |
Dockendorff Charles J | Director |
Jan 02 '24 |
Option Exercise |
38.44 |
7,551 |
290,260 |
17,482 |
Dockendorff Charles J | Director |
Jan 02 '24 |
Sale |
72.00 |
16,017 |
1,153,224 |
1,465 |
GARRETT SCOTT T | Director |
Dec 11 '23 |
Sale |
68.71 |
10,000 |
687,116 |
47,039 |
MACMILLAN STEPHEN P | Chairman, President and CEO |
Nov 29 '23 |
Option Exercise |
26.21 |
47,711 |
1,250,505 |
1,286,799 |
Capitalizzazione:
|
Volume (24 ore):